Literature DB >> 16266062

Extended remission of a recurrent median nerve malignant peripheral nerve sheath tumor after multimodal treatment. Case report.

Howard Landy1, Lynn Feun, Arnold Markoe, Sherri Patchen, Joy Bruce, Justin Marcus, Allan Levi.   

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are difficult to control despite aggressive treatment. In this report the authors describe the treatment and follow-up review of a patient with neurofibromatosis Type I who harbored a recurrent median nerve MPNST. The man underwent preoperative intraarterial and intravenous chemotherapy followed by additional surgery for gross-total removal and postoperative radiotherapy. Two courses of preoperative intraarterial cisplatin and intravenous Adriamycin produced significant tumor shrinkage. Gross-total removal of the remaining tumor without amputation of the arm was followed by fractionated radiotherapy (total minimum tumor dose 6485 cGy, maximal dose 6575 cGy). The patient is alive 9.5 years after treatment without evidence of tumor recurrence and with only focal median nerve functional deficits. A review of the patient's treatment is warranted to provide a description of a regimen that may be useful in the treatment of similar patients in the future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16266062     DOI: 10.3171/jns.2005.103.4.0760

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  2 in total

1.  Malignant peripheral nerve sheath tumor of non-neurofibromatosis type I metastasized to the cerebrospinal axis.

Authors:  Man-Kyu Park; Joo-Kyung Sung; Kyung-Hun Nam; Kyoung-Tae Kim
Journal:  J Korean Neurosurg Soc       Date:  2013-03-31

2.  A Novel Treatment Modality for Malignant Peripheral Nerve Sheath Tumor Using a Dual-Effect Liposome to Combine Photodynamic Therapy and Chemotherapy.

Authors:  Chin-Tin Chen; Po-Chun Peng; Tsuimin Tsai; Hsiung-Fei Chien; Ming-Jen Lee
Journal:  Pharmaceutics       Date:  2020-04-02       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.